Basic Study
Copyright ©The Author(s) 2024.
World J Clin Oncol. Oct 24, 2024; 15(10): 1293-1308
Published online Oct 24, 2024. doi: 10.5306/wjco.v15.i10.1293
Table 1 Sequence list of polymerase chain reaction primers
Primer name
Upstream primer sequence (5’-3’)
Downstream primer sequences (5’-3’)
AKT1GCTCAGCCCACCCTTCAAGGCTGTCATCTTGGTCAGGTGGT
PIK3CATAGTGTCCGGGAAAATGGCTGGCATGCTCTTCGATCACAG
EGFRGCCAAGGCACGAGTAACAAGCGGGCAATGAGGACATAACCAGC
BCL2AGACGGAAGAGAAATTCACTGGGCCATAATCTCATCAGGGG
IL6GTAGTGAGGTTCAAGGCTGTCATCTTGGTCAGGTGGT
GAPDHGAAGGTCGGAGTCAACGGATCCTGGAAGATGGTGATGGG
Table 2 Comparison of body weight, tumor volume, tumor weight, and tumor inhibition rate of nude mouse
Group
Number
Weight/g
Tumor volume/mm3
Tumor weight/g
Anti-tumor rate (%)
Control318.83 ± 0.15
Model315.133 ± 0.40b1641.48 ± 499.841.25 ± 0.13
Capecitabine317.633 ± 0.06b616.98 ± 156.00a0.56 ± 0.15b62.41
BXD-L316.833 ± 0.06b726.37 ± 168.48a0.77 ± 0.08b55.75
BXD-M317.673 ± 0.15b541.85 ± 95.72a0.51 ± 0.09b66.99
BXD-H317 ± 0.1b682.00 ± 281.61a0.55 ± 0.13b58.48
Table 3 IC50 screening and cell proliferation assay of Cell Counting Kit-8 for the detection of banxia xiexin decoction in MGC803
Group
24 hours OD
Proliferation rate (%)
48 hours OD
Proliferation rate (%)
Control1.88 ± 0.022.73 ± 0.04
10% BXD1.85 ± 0.01982.36 ± 0.06b86.09
20% BXD0.91 ± 0.07b45.781.53 ± 0.02b54.62
40% BXD0.48 ± 0.01b21.180.54 ± 0.02b17.09
Capecitabine1.00 ± 0.06b50.481.65 ± 0.19b59.11
LY2940021.00 ± 0.01b50.251.00 ± 0.07b34.7
BXD + LY2940020.64 ± 0.04b30.070.77 ± 0.05b26.05
Table 4 mRNA expression content in the phosphoinositide 3-kinase/protein kinase B signaling pathway (mean ± SD)
Group
EGFR
PIK3CA
AKT1
IL6
BCL2
Model1.00 ± 0.10.80 ± 0.251.01 ± 0.111.56 ± 0.062.23 ± 0.52
Capecitabine0.97 ± 0.40.34 ± 0.17a0.07 ± 0.04b1.01 ± 0.14b0.52 ± 0.13b
BXD0.79 ± 0.39a0.41 ± 0.180.04 ± 0.01b1.52 ± 0.251.09 ± 0.56a
LY2940020.25 ± 0.14b0.07 ± 0.02b0.09 ± 0.05b1.59 ± 0.170.85 ± 0.47a
BXD + LY2940020.01 ± 0.01b0.38 ± 0.210.06 ± 0.01b0.74 ± 0.07b0.40 ± 0.11b